Which aromatase inhibitors provide survival benefits?

Article

Only third-generation aromatase inhibitors (AIs) and inactivators-not earlier agents-significantly increase survival over standard hormonal treatments in women with advanced breast cancer, according to the findings of a meta-analysis of randomized, controlled trials.

Only third-generation aromatase inhibitors (AIs) and inactivators-not earlier agents-significantly increase survival over standard hormonal treatments in women with advanced breast cancer, according to the findings of a meta-analysis of randomized, controlled trials.

Davide Mauri, MD, and colleagues included 25 comparisons involving 8,504 patients and found that only the third-generation agents (vorozole, letrozole, examestane, and anastrazole) provided statistically significant survival benefits over standard hormonal treatment (relative hazard = 0.87; 95% CI; 0.82–0.93; P<0.001). First-generation aminoglutethimide and second-generation formestane and fadrozole did not.

The findings indicate that third-generation AIs and inactivators should be used as first-line treatment for advanced disease instead of tamoxifen and certainly used before progestogens.

Related Videos
Exploring the intersection of heart health and women's health | Image Credit: cedars-sinai.org
Unlocking the benefits of DHEA | Image Credit: drannacabeca.com
Unlocking the power of oxytocin | Image credit: drannacabeca.com
Revolutionizing menopause management: A deep dive into fezolinetant | Image Credit: uvahealth.com.
Deciding the best treatment for uterine fibroids | Image Credit: jeffersonhealth.org.
Clinical pearls of pediatric dermatology | Image Credit: profiles.ucsf.edu
Approaching inflammatory vulvovaginal diseases | Image Credit: profiles.ucsf.edu.
© 2024 MJH Life Sciences

All rights reserved.